Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 14/20 | 0.55 |
| ▸ | CYP4A11 | Q02928 | 14/20 | 0.55 |
| ▸ | ATR | Q13535 | 2/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22070526 | 0.90 | CYP4F2 (0.58) | CYP4F2CYP4A11ATR | |
| SCHEMBL28386468 | 0.90 | CYP4F2 (0.58) | CYP4F2CYP4A11ATR | |
| SCHEMBL29642058 | 0.84 | CYP4F2 (0.55) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL22070932 | 0.82 | CYP4A11 (0.61) | CYP4F2CYP4A11ATR | |
| SCHEMBL20590870 | 0.81 | CYP4F2 (0.79) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL22071019 | 0.80 | CYP4F2 (0.59) | CYP4F2CYP4A11ATR | |
| SCHEMBL22070818 | 0.80 | CYP4F2 (0.56) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL22070817 | 0.80 | CYP4F2 (0.56) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL22070820 | 0.80 | CYP4F2 (0.56) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL22070764 | 0.79 | CYP4F2 (0.62) | CYP4F2CYP4A11ATRPTGER3PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | CYP4F2 20/4885CYP4A11 2/4885ATR 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.